ClinConnect ClinConnect Logo
Search / Trial NCT05827042

Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion

Launched by THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA · Apr 22, 2023

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Thrombectomy Thrombolysis

ClinConnect Summary

This clinical trial is studying two different treatment approaches for patients who have a specific type of stroke called basilar artery occlusion. The researchers want to find out whether a procedure called endovascular thrombectomy (which involves removing a blood clot from the brain) is more effective on its own, or if it works better when combined with another treatment called intravenous thrombolysis (which helps dissolve blood clots). This trial is focused on patients who show symptoms of this type of stroke within 4.5 hours of the onset.

To be eligible for this study, participants need to be at least 18 years old and have certain stroke symptoms confirmed by imaging tests. They should also have a specific level of stroke severity and be able to complete follow-up appointments for 90 days. During the trial, participants will receive one of the two treatments and be monitored for effectiveness and safety. It's important to note that there are some health conditions that may disqualify potential participants, such as recent bleeding in the brain or significant other health issues. If you or a loved one may qualify and are interested, you can discuss this with your healthcare provider for more information.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients presenting with posterior circulation ischemic stroke symptoms due to basilar artery occlusion or vertebral artery occlusions that prevent antegrade flow into the basilar artery;
  • 2. Time from stroke onset to randomization within 4.5 hours of estimated time of basilar artery occlusion;
  • 3. Patient's age ≥ 18 years;
  • 4. Presence of basilar artery or vertebral artery occlusion, confirmed by CT Angiography (CTA), MR Angiography (MRA) or Digital Subtraction Angiography (DSA). In case of vertebral artery occlusion, the occlusion must completely prevent antegrade flow into the basilar artery;
  • 5. Patients presenting with acute ischemic stroke eligible to receive both endovascular thrombectomy and intravenous thrombolysis using standard criteria;
  • 6. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥ 10;
  • 7. The patient or patient's legal representative signs the informed consent form.
  • Exclusion Criteria:
  • 1. CT or MR evidence of intracerebral hemorrhage (the presence of \< 10 microbleeds is allowed);
  • 2. Pre-stroke modified Rankin scale (mRS) score ≥ 2;
  • 3. Posterior circulation Acute Stroke Prognosis Early CT Score (PC-ASPECTS) on CT/ CTA-Source Images\<6; PC-ASPECTS on magnetic resonance imaging-diffusion weighted imaging (MRI-DWI) \<5;
  • 4. Pregnant or lactating women;
  • 5. Allergy to contrast agent or nitinol alloy;
  • 6. Life expectancy\<1 year;
  • 7. CTA/MRA/DSA show vascular tortuosity, anatomical variation or artery dissection, which would make it difficult to perform endovascular treatment;
  • 8. Participating in other clinical trials;
  • 9. Systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg, which can not be controlled by antihypertensive drugs;
  • 10. Genetic or acquired hemorrhagic diathesis, lack of anticoagulant factor; oral anticoagulant with international normalized ratio (INR) \> 1.7; or novel oral anticoagulant within prior 48 hours;
  • 11. Blood glucose \<50 mg/dl (2.8 mmol/L) or \>400 mg/dl (22.2 mmol/L), platelet\< 100\*109/L;
  • 12. Renal insufficiency defined as serum creatinine \>2.0 mg/dl (or 176.8 μ mol/l), glomerular filtration rate \<30 mL/min, need for hemodialysis or peritoneal dialysis;
  • 13. Patients who cannot complete 90-day follow-up (such as patients without fixed residence, overseas patients, etc);
  • 14. The patient has acute ischemic cerebral infarction within 3 months from randomization;
  • 15. The patient had a history of or clinical suspicion for cerebral vasculitis or infectious endocarditis;
  • 16. The patient has nervous system disease or mental disorder before stroke onset, which may affect the assessment of their condition;
  • 17. CT or MR examination showed large cerebellar infarction with obvious space occupying effect and compression of the fourth ventricle;
  • 18. Patients with extensive bilateral thalamic or extensive bilateral brainstem infarction on CT or MR examination;
  • 19. CTA/MRA/DSA show both anterior and posterior circulation large vessel occlusion;
  • 20. Patients with intracranial tumors (except small meningiomas);
  • 21. Patients who received intravenous thrombolytics treatment before the randomization.

About The First Affiliated Hospital Of University Of Science And Technology Of China

The First Affiliated Hospital of the University of Science and Technology of China is a leading medical institution dedicated to advancing healthcare through innovative clinical research and patient care. As an integral part of one of China's premier universities, the hospital combines cutting-edge medical technology with a commitment to excellence in education and research. With a diverse team of experienced healthcare professionals and researchers, the hospital actively engages in clinical trials aimed at developing new treatments and improving patient outcomes across various medical fields. Its strategic focus on collaboration and scientific inquiry positions it as a prominent sponsor in the realm of clinical trials.

Locations

Hefei, Anhui, China

Patients applied

0 patients applied

Trial Officials

Wei Hu, MD

Study Chair

The First Affiliated Hospital of University of Science and Technology of China

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported